Cellular Activation Insulin Therapy

• US 20110144011A1
• Filed: 12/14/2010
• Published: 06/16/2011
• Est. Priority Date: 12/14/2009
• Status: Active Grant

• Current Assignee: Sabre Holdings Group, LLC, Sun Pacific Group, Inc.
• Original Assignee: Marc Rose, Michael Mccarthy
• Inventors: McCarthy, Michael, Rose, Marc
• Granted Patent: US 8,394,766 B2
• Time in Patent Office: Days
• US Class Current: 514/6.5
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection

Abstract

Diabetic and other patients are treated using an aggressive form of Pulsed Insulin Therapy in which a pre-treatment blood sugar level in the patient of at least 250-300 mg/dL, and the patient is treated with at least first and second cycles, each cycle comprising (1) pulsing a recombinant human insulin to the patient in concentrations of more than 10% to achieve a target intra-treatment blood sugar level (BSL) swing of more than 100 mg/dL, and (2) raising the blood sugar level to at least 250-300 mg/dL.

Claims

1. A method of treating a patient, comprising:

establishing a pre-treatment blood sugar level in the patient of at least 250-300 mg/dL;

treating the patient with at least first and second cycles, each cycle comprising (1) pulsing a fast acting insulin to the patient in a concentration of 10%±

3% to achieve a target intra-treatment blood sugar level (BSL) swing of more than 100 mg/dL, and (2) raising the blood sugar level to at least 250-300 mg/dL.

2. The method of claim 1, wherein the fast acting insulin comprises a recombinant human insulin.

3. The method of claim 2, wherein the concentration of insulin being pulsed is 20% insulin±

3%.

4. The method of claim 2, wherein the concentration of insulin being pulsed is 30% insulin±

3%.

5. The method of claim 2, wherein the concentration of insulin being pulsed is 40% insulin±

3%.

6. The method of claim 2, wherein the target intra-treatment blood sugar level (BSL) swing of at least 125 mg/dL.

7. The method of claim 2, wherein the target intra-treatment blood sugar level (BSL) swing of at least 150 mg/dL.

8. The method of claim 2, wherein the step of raising the blood sugar level comprises administering sucrose to the patient.

9. The method of claim 2, wherein the step of raising the blood sugar level comprises administering food to the patient.

10. The method of claim 2, further comprising pulsing the insulin to the patient at irregular intervals.